Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells

Journal of Infectious Diseases

Volumn 186, Issue 9, 2002, Pages 1242-1252

  Marovich, Mary A ^a   Mascola, John R ^b   Eller, Michael A ^a   Louder, Mark K ^b   Caudrelier, Pierre A ^e   El Habib, Raphaelle ^f   Ratto Kim, Silvia ^a   Cox, Josephine H ^a   Currier, Jeffrey R ^a   Levine, Bruce L ^c   June, Carl H ^c   Bernstein, Wendy B ^a   Robb, Merlin L ^a   Schuler Thurner, Beatrice ^g   Steinman, Ralph M ^d   Birx, Deborah L ^a   Schlesinger Frankel, Sarah ^a  

^a US Military HIV Research Program   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e IDM Biotech   (Canada)

^f SANOFI PASTEUR   (France)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT CANARYPOX HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CANARYPOX VIRUS; CELL ACTIVITY; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS RECOMBINANT;

AIDS VACCINES; ANTIGENS, CD; CANARYPOX VIRUS; CELL SEPARATION; DENDRITIC CELLS; GENE PRODUCTS, GAG; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0036839319     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/344302     Document Type: Article

References (47)

1. AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgP120. J Infect Dis 2001;183:563-70.
2. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp12O SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998;12:2407-15.
3. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001;183:1343-52.
4. + cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999;180:290-8.
5. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:1230-46.
6. Salmon-Ceron D, Excler JL, Finkielsztejn L, et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses 1999;15:633-45.
7. Tubiana R, Gomard E, Fleury H, et al. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (AL-VAC-HIV): A double-blind controlled randomized study of safety and immunogenicity. AIDS 1997;11:819-20.
8. Klein M. Current progress in the development of human immunodeficiency virus vaccines: Research and clinical trials. Vaccine 2001;19:2210-5.
9. Dolin R. HIV vaccines for prevention of infection and disease in humans. Infect Dis Clin North Am 2000;14:1001-16.
10. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
11. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001;106:271-4.
12. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 2001;22:102-7.
13. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-18.
14. Schuler G, Brang D, Romani N. Production and properties of large numbers of dendritic cells from human blood. Adv Exp Med Biol 1995;378:43-52.
15. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137:1142-62.
16. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med 1974;139:380-97.
17. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptidepulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
18. Wen YJ, Ling M, Bailey-Wood R, Lim SH. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998;4:957-62.
19. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
20. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2: 52-8.
21. + progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8.
22. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513-9.
23. Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999;104:173-80.
24. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-8.
25. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-22.
26. Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001;22:394-400.
27. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
28. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135-42.
29. Ignatius R, Marovich M, Mehlhop E, et al. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J Virol 2000;74:11329-38.
30. Motta I, Andre F, Lim A, et al. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol 2001;167:1795-802.
31. Jonuleit H, Giesecke-Tuettenberg A, Tuting T. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001;93:243-51.
32. Engelmayer J, Larsson M, Subklewe M, et al. Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion. J Immunol 1999;163:6762-8.
33. Jenne L, Hauser C, Arrighi JF, Saurat JH, Hugin AW. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: Abortive infection but reduced APC function. Gene Ther 2000;7:1575-83.
34. Kruse M, Rosorius O, Kratzer F, et al. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J Virol 2000;74:7127-36.
35. Salio M, Cella M, Suter M, Lanzavecchia A. Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol 1999;29:3245-53.
36. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999;29:964-72.
37. Cumberbatch M, Dearman RJ, Kimber I. Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration. Immunology 1997;92:388-95.
38. Cumberbatch M, Griffiths CE, Tucker SC, Dearman RJ, Kimber I. Tumour necrosis factor-alpha induces Langerhans cell migration in humans. Br J Dermatol 1999;141:192-200.
39. Steinman R, Hoffman L, Pope M. Maturation and migration of cutaneous dendritic cells. J Invest Dermatol 1995:105(Suppl 1):2S-7S.
40. Sallusto F, Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000;177:134-40.
41. Caux C, Ait-Yahia S, Chemin K, et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 2000;22:345-69.
42. Sallusto F, Schaerti P, Loetscher P, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998;28:2760-9.
43. Macagno A, Gilliet M, Sallusto F, Lanzavecchia A, Nestle FO, Groettrup M. Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol 1999;29:4037-42.
44. Macagno A, Kuehn L, de Giuli R, Groettrup M. Pronounced up-regulation of the PA28alpha/beta proteasome regulator but little increase in the steady-state content of immunoproteasome during dendritic cell maturation. Eur J Immunol 2001;31:3271-80.
45. Manickasingham S, Reis e Sousa C. Microbial and T cell-derived stimuli regulate antigen presentation by dendritic cells in vivo. J Immunol 2000;165:5027-34.
46. + T-cell responses from chronically infected individuals. J Virol 2001;75:2142-53.
47. Abdel-Motal UM, Friedline R, Poligone B, Pogue-Caley RR, Frelinger JA, Tisch R. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice. Clin Immunol 2001;101:51-8.